《大行報告》麥格理上調海吉亞醫療(06078.HK)目標價至66.72元 評級「跑贏大市」
麥格理發表研報指,海吉亞醫療(06078.HK)已建立一套強大的收購、建造及運營醫院獨立系統,能夠在3至9個月達到收支平衡,在3至4年內入住率可達到100%。雖然預期未來3年將要開業6家新醫院,但擴展網絡將支持公司在未來3年內輕易實現30%複合年增長率。
該行指,管理層回歸料將進一步增強投資者信心,公司著重於提高服務水平,提供從早期篩查到康復的整體腫瘤學相關服務,料有助提高品牌知名度及吸引更多病人到訪,預期每位患者平均支出繼續增加,增長14%至1.3萬元人民幣,同時有助公司分散較沉重的政策風險。
麥格理指出,擴張仍是海吉亞醫療的主要增長動力,管理層透露未來將新增2至3家新醫院,預測將在未來8年每年收購或建造3家醫院,短期內預計今年及明年每年將落實13項放射治療合同,將今明兩年每股盈利預測上調10%及16%,目標價升11%至66.72元,予「跑贏大市」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.